MedTrace Logo

Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis

NCT02228213 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2017-07-14

No results posted yet for this study

Summary

The purpose of this study is to determine whether MIS416 administered once weekly over 12 months is safe, tolerable, and improves a range of signs and symptoms associated with secondary progressive multiple sclerosis.

Conditions

  • Secondary Progressive Multiple Sclerosis

Interventions

BIOLOGICAL

MIS416

Intravenous administration weekly for 52 weeks

DRUG

Saline

Intravenous administration weekly for 52 weeks

Sponsors & Collaborators

  • Syneos Health

    collaborator OTHER

  • Innate Immunotherapeutics

    lead INDUSTRY

Principal Investigators

  • Michael Silverman · Innate Immunotherapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2017-05-31
Completion
2017-06-30

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02228213 on ClinicalTrials.gov